Spots Global Cancer Trial Database for Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Official Title: An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)
Study ID: NCT00286793
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
, Hot Springs, Arkansas, United States
, Fort Meyers, Florida, United States
, Chicago, Illinois, United States
, Fridley, Minnesota, United States
, Albuquerque, New Mexico, United States
, Syracuse, New York, United States
, Wilmington, North Carolina, United States
, Portland, Oregon, United States
, Hilton Head Island, South Carolina, United States
, Germantown, Tennessee, United States
, Memphis, Tennessee, United States
, Nashville, Tennessee, United States
, Richardson, Texas, United States
Contact Details
Name: Lance Leopold, MD
Affiliation: Ascenta Therapeutics, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
